Aurinia Pharmaceuticals Inc (NAS:AUPH)
$ 5.42 0.04 (0.74%) Market Cap: 775.16 Mil Enterprise Value: 538.07 Mil PE Ratio: 0 PB Ratio: 2.17 GF Score: 73/100

Q3 2020 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Nov 10, 2020 / 09:30PM GMT
Release Date Price: $13.57 (-1.88%)
Operator

Greetings, and welcome to the Aurinia Pharmaceuticals Third Quarter 2020 results.

(Operator Instructions)

Please note that this conference is being recorded. I will now turn the conference over to our host, Dr. Glenn Schulman, Head of IR. Thank you. You may begin.

Glenn Schulman
Aurinia Pharmaceuticals Inc. - SVP of Corporate Communications & IR

Thanks, Diego, and good afternoon, everyone. Welcome to Aurinia's Third Quarter 2020 Results Conference Call. Joining me on the call today from the Aurinia team are Mr. Peter Greenleaf, President and CEO; Mr. Max Colao, Chief Commercial Officer; Mr. Joe Miller, Chief Financial Officer; and Dr. Neil Solomons, Chief Medical Officer here at Aurinia. This afternoon, we issued our press release and associated financial statement package detailing the third quarter 2020 financial results, both of which are available on our website at www.auriniapharma.com. And filed on a Form 6-K with the SEC as well. Before jumping into some brief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot